Resources Waldenström’s macroglobulinaemia (WM)

This is a promotional website intended for healthcare professionals in the UK and Ireland only.

BRUKINSA WM NICE Approval Discussion

Date of preparation: January 2025. 0922-BRU-PRC-084

Diagnosis, Clinical Features and Indications for WM Therapy

Date of preparation: January 2025. 1122-BRU-PRC-051

An In-Depth Look at the ASPEN Study – Dr Roger Owen and Dr Shirley D’Sa

Date of preparation: January 2025. 1122-BRU-PRC-100

Practical Considerations of BRUKINSA – Dr Jaimal Kothari 

Date of preparation: January 2025. 1122-BRU-PRC-102

Current Treatments: BSH Guidelines – Dr Dima El-Sharkawi

Date of preparation: January 2025. 1122-BRU-PRC-097

Welcome to “Real world experience treating WM and what’s next for CLL” – Dr Robert Mulrooney

Date of preparation: January 2025. 0723-BRU-PRC-076

Waldenström’s macroglobulinaemia/ lymphoplasmacytic lymphoma: An introduction – Prof George Follows

Date of preparation: January 2025. 0723-BRU-PRC-077

Case-based panel discussion – Dr Pam McKay

Date of preparation: January 2025. 0723-BRU-PRC-078

Case-based panel discussion – Dr Sarah Lawless

Date of preparation: January 2025. 0723-BRU-PRC-079

Case-based panel discussion – Dr Vishal Jayakar

Date of preparation: January 2025. 0723-BRU-PRC-080

Closing


Date of preparation: January 2025. 0723-BRU-PRC-082

The Changing Landscape of WM in Scotland with Dr Pam McKay

Date of preparation: January 2025. 1122-BRU-PRC-067

Adverse events should be reported

United Kingdom (incl. Northern Ireland): Healthcare Professionals are asked to report any suspected adverse reactions via Yellow Card Scheme found at https://yellowcard.mhra.gov.uk/.
Ireland: Healthcare Professionals are asked to report any suspected adverse reactions via HPRA at www.HPRA.ie.

All adverse events (UK and Ireland) should also be reported to BeiGene at adverse_events@beigene.com; (UK: 08009176799; Ireland: 1800812061).

For medical information, please contact: UK: 08004320266, Ireland: 1800946589 or email: medicalinformationEU@beigene.com

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

October 2023 [0823-BRU-PRC-171]

Back to top

Brukinsa®▼ UK and Ireland healthcare professional website

This website contains information on BRUKINSA (zanubrutinib) and is intended for healthcare professionals in the UK and Ireland only.

To direct you to the most appropriate information, please confirm you are a UK or Ireland Healthcare Professional.

If you are not a UK or Ireland Healthcare Professional, you will be directed to the BRUKINSA Patient Information leaflet.

Are you a UK or Ireland Healthcare Professional?

0823-BRU-PRC-184 | September 2023

No, I am not